<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) leakage plays a role in the pathogenesis of many pathological states of the brain including <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and some <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In recent years, erythropoietin (EPO) has been shown to exert neuroprotection in many pathological conditions including <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in the brain </plain></SENT>
<SENT sid="2" pm="."><plain>This study aimed to investigate the effects of EPO on <z:chebi fb="2" ids="33602">BBB</z:chebi> integrity, <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation following global <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>/reperfusion in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Wistar male rats were divided into four groups (each group n=8); Group I; control group (sham-operated), Group II; <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion group, Group III; EPO treated group (24 h before decapitation--000 U/kg r-Hu EPO i.p.), Group IV; EPO+ <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion group (24 h before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion--3000 U/kg r-Hu EPO i.p.) </plain></SENT>
<SENT sid="4" pm="."><plain>Global <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> was produced by the combination of bilateral common carotid <z:mp ids='MP_0006134'>arteries occlusion</z:mp> and hemorrhagic <z:hpo ids='HP_0002615'>hypotension</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Macroscopical and spectrophotometrical measurement of Evans Blue (EB) leakage was observed for <z:chebi fb="2" ids="33602">BBB</z:chebi> integrity </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size was calculated based on 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) staining </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> peroxidation in the brain tissue was determined as the concentration of <z:chebi fb="0" ids="33202">thiobarbituric acid</z:chebi>-reactive substances (TBARS) for each group </plain></SENT>
<SENT sid="8" pm="."><plain>Ischemic insult caused bilateral and regional <z:chebi fb="2" ids="33602">BBB</z:chebi> breakdown (hippocampus, cortex, corpus striatum, midbrain, brain stem and thalamus) </plain></SENT>
<SENT sid="9" pm="."><plain>EPO pretreatment reduced <z:chebi fb="2" ids="33602">BBB</z:chebi> disruption, <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="39" ids="44785">peroxide</z:chebi> levels in brain tissue with 20 min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and 20 min reperfusion </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that EPO plays an important role in protecting against <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>/reperfusion through inhibiting <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation and decreasing <z:chebi fb="2" ids="33602">BBB</z:chebi> disruption </plain></SENT>
</text></document>